Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services.

“Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s most difficult challenges, drug discovery,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space.”

Recursion plans to utilize its vast proprietary biological and chemical dataset, which exceeds 23 petabytes and 3 trillion searchable gene and compound relationships, to accelerate the training of foundation models on NVIDIA DGX™ Cloud for possible commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery. NVIDIA will also help optimize and scale Recursion foundation models leveraging the NVIDIA AI stack and NVIDIA’s full-stack computing expertise. BioNeMo was announced earlier this year as a cloud service for generative AI in drug discovery, offering tools to quickly customize and deploy domain-specific, state-of-the-art biomolecular models at-scale through cloud APIs. Recursion anticipates using this software to support its internal pipeline as well as its current and future partners.

'Generative AI is a revolutionary tool to discover new medicines and treatments,” said Jensen Huang, founder and CEO of NVIDIA. “We are delighted to collaborate with Recursion’s world-class team, which is doing pioneering work in digital biology and chemistry with NVIDIA DGX and NVIDIA AI software to accelerate the development of the world’s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.”

Recursion, through its recent acquisition of Valence Discovery, aims to accelerate the development of new technologies to feed the biopharma industry, while simultaneously democratizing access to large-scale models that have maximum impact in drug discovery.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon 'forward-looking statements' within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the acceleration and advancement of development of AI foundation models, as well as optimizing, licensing, and distributing such models; using BioNeMo software to support Recursion’s internal pipeline and well as Recursion’s current and future industry partners; Recursion accelerating development of new technologies through its Valence Discovery acquisition; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.


Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

THỦ THUẬT HAY

Cách nhận thông báo khi để quên AirPods Pro trên iOS 15 cực kỳ hữu ích

Trên iOS 15, Apple đã thêm tính năng thông báo khi bạn bỏ quên AirPods Pro với ứng dụng Tìm (Find My) để biết vị trí tai nghe của mình. Sau đây là cách nhận thông báo khi để quên AirPods Pro...

Các bước đơn giản giúp ẩn thanh Dock trên iPhone mà không cần jailbreak

Hệ điều hành iOS của Apple nổi tiếng với việc bảo mật và không thể tùy biến như hệ sinh thái android. Điều đó khiến cho người dùng đôi khi sẽ chán với giao diện iOS.

Cách xem trực tiếp bóng đá C1 trên UEFA tại Việt Nam

Vì vấn đề bản quyền và một vài yếu tố khác nên người hâm mộ Việt Nam không được theo dõi các trận đấu Champions League và Europa League trên sóng truyền hình.

[Thủ thuật] Cài đặt IDM extension vào trình duyệt Microsoft Edge để tự động bắt link

Kể từ Windows 10 Fall Creators thì trình duyệt Edge đã tốt hơn hẳn và mình cũng đã trở lại dùng làm trình duyệt chính. Mọi thứ đều ổn trừ một thứ … Internet Download Mananger - phần mềm hỗ trợ download này hầu như

Boximize - Tiện ích giúp quản lý công việc một cách khoa học

Về cơ bản, Boximize sẽ thay thế cho ứng dụng ghi chú mặc định trên thiết bị iOS với nhiều tính năng hỗ trợ hơn, cho phép người dùng tùy chỉnh các ghi chú đó để phù hợp hơn với nhu cầu sử dụng, dễ dàng theo dõi hoặc

ĐÁNH GIÁ NHANH

Đánh giá nhanh miếng dán cường lực 3D tràn màn hình cho iPhone

Trong bài này mình chia sẻ với anh em về trải nghiệm của mình sau khi sử dụng miếng dán cường lực 3D cho iPhone màn hình bo 2.5D sau hơn 2 tuần sử dụng. Cảm giác đầu tiên là nặng, rất nặng.

Đánh giá thiết bị mở rộng sóng Wi-Fi: D-Link DAP-1620

Thông thường khi bạn lắp mạng Internet với các nhà mạng thì hiện tại gần như tất cả các...

Đánh giá AMD Ryzen 7 7800X3D mạnh hơn 30% hiệu quả hơn khi chơi game

AMD Ryzen 7 7800X3D là con chip hỗ trợ chơi game chuyên nghiệp mạnh nhất từ trước đến nay. CPU này là sự lựa chọn lý tưởng cho các game thủ với 8 lõi, 16 luồng cùng 104 bộ nhớ cache (32 MB CCD, 64 MB V-Cache + 8 MB